Construction of chimeric antigen receptor targeting CD20 antigen and activity identification of engineered T cells thereof
Provided are a chimeric antigen receptor targeting CD20 antigen and a preparation method thereof. The extracellular antigen binding domain of the chimeric antigen receptor includes an antibody heavy chain variable region shown in SEQ ID NO: 7 or 9 or 33 and an antibody light chain variable region shown in SEQ ID NO: 11 or 13 or 35, and is capable of killing tumor cells.
1. A method of treating a B-cell malignancy, the method comprising administering a T cell expressing a chimeric antigen receptor (CAR) to a subject in need thereof, wherein the CAR comprises an anti-CD20 antigen binding region comprising:
(i) a heavy chain variable region (V H ) having an amino acid sequence set forth in SEQ ID NO: 7, and
(ii) a light chain variable region (V L ) having an amino acid sequence set forth in SEQ ID NO: 11,
wherein V H is located at the N-terminus of V L ,
wherein the CAR comprises an amino acid sequence set forth in SEO ID NO: 5.
2. The method of claim 1 , wherein the B-cell malignancy is Hodgkin's lymphoma, non-Hodgkin's lymphoma, leukemia, and/or multiple myeloma.
3. The method of claim 1 , wherein the B-cell malignancy is acute lymphocytic leukemia (ALL), chronic lymphocytic leukemia (CLL), e B-cell acute lymphoblastic leukemia (B-ALL), B-cell leukemia, or B cell lymphoma.
4. The method of claim 1 , wherein the immune T cell is administered by infusion, injection, transfusion, implantation, and/or transplantation.
5. The method of claim 1 , wherein the T cell is administered intravenously, subcutaneously, intranodally, intramedullary, intramuscularly, or intraperitoneally.
6. The method of claim 1 , wherein the T cell is administered via intravenous infusion.
7. The method of claim 1 , wherein the T cell is allogeneic or autologous.
8. The method of claim 1 , wherein the subject is a human.